In this Issue
- The Psychedelic Blame Game: NYT Report Fuels Controversy Over MDMA Rejection
- Mixed Messages on Psymposia’s Role
- Lykos and MAPS Seize the Opportunity
- Political Pragmatism Sparks Backlash Among Some Supporters
- Psychedelic Drug Developers Reflect on “Lykos-Specific Issues” and the Road Ahead
- FDA “Wanted to Approve” MDMA, Says MindMed Exec
- Trump on Psychedelics; “Nothing” Lies Beyond Psychological Support; Trial Site Availability Limits Psychedelic Drug Development
- GH’s 5-MeO-DMT Data and RFK Jr. Confirmation Send Psychedelics Stocks Soaring
- Other Stories, Including: Beckley Shares Data from Phase 2a 5-MeO-DMT Study • MindMed Doses First Patient in Second Phase 3 Study of LSD in GAD • California Medical Association Adopts Resolution Calling for Reduced Regulatory Burdens on Psilocybin, AMA to Vote in June • UK Refreshes ILAP Program • Case Report Details Suicide of Psilocybin-Assisted Therapy Patient • International Collaboration Between UK, Canadian, and U.S. Psychedelic Industry Groups Announced • Tacoma City Council Makes ‘Entheogen-Related Activities’ Low Law Enforcement Priority • PitchBook 97% Confident Beckley IPOs this Year • PharmAla Signs Advisory Agreement with Matthew Azrieli • Ambio Life Sciences Publishes Case Report on Ibogaine in 2 MS Patients • Compass-Backed Trigger Law Bills Appear in Iowa, Kansas • U.S. Embassy in Peru and Costa Rica Authorities Warn Against Psychedelics • 2025 Florida Farm Bill Clamps Down on Amanita muscaria.
***
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue